One emerging treatment option for several antibody-mediated autoimmune diseases is the anti-CD38 antibody daratumumab, which depletes autoantibody-secreting plasma cells. Methods We treated two ...

The purpose of this study is to assess the effectiveness of daratumumab SC in treating patients with monoclonal immunoglobulin deposits (PGNMID) by assessing improvement in proteinuria at 12 months.